Primary reperfusion in acute right ventricular infarction: An observational study
Eulo Lupi-Herrera1, Héctor González-Pacheco1, Ursulo Juárez-Herrera1
1Eulo Lupi-Herrera, The American British Cowdray Medical Center I.A.P., Mexico City 14080, Mexico.
World Journal of Cardiology
|February 15, 2014
Summary
Primary reperfusion therapy significantly reduces mortality in acute right ventricular infarction (RVI). Primary percutaneous coronary intervention (PPCI) is superior to thrombolytic therapy (TT), especially for patients with cardiogenic shock (CS).
Area of Science:
- Cardiology
- Interventional Cardiology
- Acute Myocardial Infarction
Background:
- Acute right ventricular infarction (RVI) poses a significant mortality risk.
- The effectiveness of primary reperfusion therapy (RT) in mitigating RVI mortality requires further investigation.
- Stratification of RVI patients into different risk classes (e.g., with or without right ventricular failure, cardiogenic shock) is crucial for treatment evaluation.
Purpose of the Study:
- To evaluate the impact of primary reperfusion therapy (RT) on both early and late mortality in patients with acute right ventricular infarction (RVI).
- To compare the efficacy of different reperfusion strategies, specifically thrombolytic therapy (TT) versus primary percutaneous coronary intervention (PPCI).
- To assess outcomes across different RVI severity classes, including those with and without right ventricular failure (RVF) and cardiogenic shock (CS).
Main Methods:
- A prospective study involving 679 RVI patients categorized into three classes: A (no RVF), B (RVF), and C (CS).
- Patients received either thrombolytic therapy (TT) or primary percutaneous coronary intervention (PPCI) as reperfusion strategies.
- Assessment of reperfusion success (TIMI 3-flow) and comparison of mortality rates (early and late) between treatment groups and RVI classes.
Main Results:
- Primary percutaneous coronary intervention (PPCI) demonstrated superior outcomes compared to thrombolytic therapy (TT) across all RVI classes (A, B, and C).
- PPCI significantly reduced both in-hospital and long-term mortality rates in RVI patients, particularly those with cardiogenic shock (CS).
- Mortality rates decreased substantially with RT compared to no RT, with PPCI showing the greatest benefit (e.g., Class C mortality reduced from 80% to 44% in-hospital).
Conclusions:
- Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for acute right ventricular infarction (RVI), offering superior short- and long-term survival benefits over thrombolytic therapy (TT).
- Patients experiencing RVI with cardiogenic shock (CS) should be promptly referred for PPCI at specialized centers.
- Timely and effective reperfusion therapy, especially PPCI, is critical for improving outcomes in all categories of RVI.
